Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry - Wikidata - wikimedia - TriplyDB

Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry

Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry

http://www.wikidata.org/entity/Q28258153

about

Cardiomyopathy and response to enzyme replacement therapy in a male mouse model for Fabry disease Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease Fabry disease in latin america: data from the fabry registry.Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry.Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?Effectiveness of enzyme replacement therapy in Fabry disease: Long term experience in Argentina.The Genetic Challenges and Opportunities in Advanced Heart Failure Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34+ Cells for Correction of Fabry Disease Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.Use of lissamine rhodamine ceramide trihexoside as a functional assay for alpha-galactosidase A in intact cells FabryScan: a screening tool for early detection of Fabry disease.Prevalence of Raynaud phenomenon and nailfold capillaroscopic abnormalities in Fabry disease: a cross-sectional study Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial.Innate and Adaptive Immune Response in Fabry Disease Paediatric Fabry disease: prognostic significance of ocular changes for disease severity.Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy.Renal complications of Fabry disease in children FAbry STabilization indEX (FASTEX): an innovative tool for the assessment of clinical stabilization in Fabry disease.Cardiac device implantation in Fabry disease: A retrospective monocentric study.Fabry disease: Evidence for a regional founder effect of the GLA gene mutation 30delG in Brazilian patients.Fabry disease: a review of current management strategies.Effects of enzyme replacement therapy in Fabry disease--a comprehensive review of the medical literature.Fabry disease 'The New Great Imposter': results of the French Observatoire in Internal Medicine Departments (FIMeD).Fabry disease, enzyme replacement therapy and the significance of antibody responses.Angiokeratoma: decision-making aid for the diagnosis of Fabry disease.Fabry disease: raising awareness of the disease among physicians.Fabry disease practice guidelines: recommendations of the National Society of Genetic Counselors.Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: Underdiagnosis of late-onset phenotype.The Impact of Fabry Disease on Reproductive Fitness.Renal phospholipidosis possibly induced by ranolazine.Gastrointestinal phenotype of fabry disease in a patient with pseudoobstruction syndrome.Fabry disease in Argentina: an evaluation of patients enrolled in the Fabry Registry.Pathomechanisms of renal Fabry disease.Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice.Fabry disease and multiple sclerosis misdiagnosis: the role of family history and neurological signs.Therapeutic goals in the treatment of Fabry disease.Fabry disease: is there a role for enzyme replacement therapy?Fabry disease mimicking hypertrophic cardiomyopathy: genetic screening needed for establishing the diagnosis in women.Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry.Biomarkers of Myocardial Fibrosis: Revealing the Natural History of Fibrogenesis in Fabry Disease Cardiomyopathy.

P2860

Q28730130-A024B73C-17FA-47E7-AD84-3D1D6AE698D5 Q28748170-9089931E-8BAD-4E42-BD90-241690DAD217 Q30592389-D06A0758-79DE-486A-BF13-A9DD21390E07 Q31060724-3D8D99C3-27A9-4A09-B8F2-5756613F20DC Q33645550-8C5D23BF-C4AF-4476-8A97-145ACA7F3DB7 Q33652370-46E666FE-55BD-4C2E-8910-D9F086341520 Q33653498-C502F258-94F1-4D51-BAEC-48079970C3F2 Q33752595-981A6BC5-0CEF-4D03-980D-0DF2684E2BB5 Q33886219-7E237938-C275-4727-89FC-75B22C45AE83 Q34053196-3A301F76-9266-41B3-9ABD-77638825CBA5 Q34641339-635993D0-6D3A-4A88-8740-C0D9A2EFF8C5 Q34669916-2369C6E7-5548-4E82-BABD-601B73669DD3 Q35587768-121530A8-B728-4BCA-A192-1306C453CBA6 Q35800976-80AF4616-74FB-4BC6-B2C4-2A1511DFBBDF Q36194571-F9DAAAAF-C250-4B58-9614-401529839657 Q36475780-B32E733E-4B4A-4A8F-A43F-D96ED70FA807 Q37265117-EC08BB48-59AD-4DDF-8CDA-D45F1E8C0AA5 Q37284141-CAF62543-CC17-4A43-AD33-099DF402B6CC Q37328866-6D38CDCA-8D88-42DD-9012-2EE16D035250 Q37434242-F6A7D0D6-A2A5-4FA1-8013-5DDA50F83032 Q37775790-58D8E3FB-5276-4541-9292-0785FD0B5F6C Q37801828-5BEFF241-A901-42C8-85F1-EBBC86E32999 Q37881984-2646FBE3-8B2C-4776-B7D0-56089D305A2C Q37950838-6B86FC06-CEAF-4823-966D-CFA55953F90B Q37997470-35EB960A-B239-41CD-A5E9-77C4AD1CC611 Q38052848-9C4B2919-1ED5-455C-B5B5-F56FF13BCC23 Q38122106-18D84593-84B2-47A2-86FC-622A68DFBF86 Q38672018-BEA08C60-2DF3-42BB-838B-891115845739 Q38889928-3AE4269C-18C0-470E-8B2E-3C44D74E5787 Q39369271-819EBAB6-D30D-42D9-A58B-4FC5C0CE98B5 Q41810342-9C1DF690-0ADD-47E2-9215-FA7D35AE2D2D Q44063760-E492DE25-D2B2-4ECB-B56E-422753B124BC Q48287690-8BFFA3FB-BD57-4009-BCF5-0DA94A050BF1 Q50089735-2DA25061-78F0-4ED2-A4BB-3C23BE709E70 Q50318581-FA84DF81-5CFC-4B41-9E56-482148C9EB8A Q50436079-A11FD29A-078D-4813-933F-555794D283CD Q51004353-DA9E2CC4-515C-425D-82BC-D53A371FA9F8 Q51563942-B3A0F503-E87C-4AEF-9856-FF7FC2C7C6B6 Q51835868-598258F4-EADB-493A-A0F9-28386EE27790 Q52726808-AA664D02-DDA2-4134-8A2D-BBAE65D0BFE6

P2860

Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry

http://www.wikidata.org/entity/Q28258153

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Life expectancy and cause of d ...... ndings from the Fabry Registry

@ast

Life expectancy and cause of d ...... ndings from the Fabry Registry

@en

Life expectancy and cause of d ...... ndings from the Fabry Registry

@nl

type

label

Life expectancy and cause of d ...... ndings from the Fabry Registry

@ast

Life expectancy and cause of d ...... ndings from the Fabry Registry

@en

Life expectancy and cause of d ...... ndings from the Fabry Registry

@nl

prefLabel

Life expectancy and cause of d ...... ndings from the Fabry Registry

@ast

Life expectancy and cause of d ...... ndings from the Fabry Registry

@en

Life expectancy and cause of d ...... ndings from the Fabry Registry

@nl

P1433

Q28258153-85A74A4E-E2C9-4501-BB41-B0A10C933F7E

P1476

Q28258153-FF4A189A-38E1-4B58-B11B-42F3E7B39E93

P2093

Q28258153-20A0F052-E4BF-4A43-9F4D-DE8C1EA021C6

Q28258153-7F9B5E27-AC94-4DA3-A4AE-E80D0AB2D82C

Q28258153-AA6BE237-ABFA-479A-BA55-244E4C2902F0

Q28258153-CEB107A2-9186-40C0-9AE0-83D3BB8582A8

Q28258153-E921C702-5F9E-4D7A-B9BA-AE7F871E6673

P2860

Q28258153-108EFAF1-420A-4EE9-BCFC-EA012C25C69E

Q28258153-1B75431C-C336-4854-869E-8BFF07FA587E

Q28258153-25229C55-ABFD-4B11-943A-43A73E450039

Q28258153-2FFD65AB-505F-4043-A578-C3BAFFAE671B

Q28258153-31366FF8-30C9-482C-8B39-139EB898C942

Q28258153-34AE109E-A6AB-4CDC-840B-4A3455863DAA

Q28258153-3766BD0B-AABC-4CA9-96AE-A8AC99053B4F

Q28258153-3F0A660B-E12A-415A-8255-309551445E28

Q28258153-4E9E46B5-8B69-4933-ABC9-0AFFDCC61908

Q28258153-89081F32-BC4A-48B0-88B7-1D2ECD8E2D23

P2888

Q28258153-A0A4BA93-74D6-48D1-AF59-0B45D808FDE3

P304

Q28258153-30DEBF3A-FEE9-4CB8-8CAE-F97C3AA26BF9

P31

Q28258153-B744B4A6-8401-486D-A0B5-9E5C69C8028F

P3181

Q28258153-40F625F9-6F41-4C53-A43D-80FFFEF4586E

P356

Q28258153-C7785708-D940-4175-9A0F-D8C6D958EB89

P407

Q28258153-CC5C9E10-7D59-4576-ABE2-CA07ECF6EA30

P433

Q28258153-F0F970EC-11E1-4C49-BBAA-2AD578374DD6

P478

Q28258153-446335CF-FAAE-4726-94DD-AA1224B9C037

P577

Q28258153-682AC1E7-7D60-497A-B89C-E53E450CFEAB

P6179

Q28258153-543E36B1-6D64-4204-A4EA-9B2F655C4911

P698

Q28258153-7167F4B1-B2F4-4F21-9FA2-8B4B1B7AB857

P921

Q28258153-4304A9EA-48EA-46C5-ABA8-3D91ACF75FC6

P3181

P356

GIM.0B013E3181BB05BB

P1433

Genetics in Medicine

P1476

Life expectancy and cause of d ...... ndings from the Fabry Registry

@en

P2093

Manesh R Patel

http://www.w3.org/2001/XMLSchema#string

Maryam Banikazemi

http://www.w3.org/2001/XMLSchema#string

Philip Lee

http://www.w3.org/2001/XMLSchema#string

Roberta Lemay

http://www.w3.org/2001/XMLSchema#string

Stephen Waldek

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies

Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy.

Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry.

Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

Prevalence of lysosomal storage disorders.

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males

P2888

gim.0b013e3181bb05bb

P304

790-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3210359

http://www.w3.org/2001/XMLSchema#string

P356

10.1097/GIM.0B013E3181BB05BB

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1007386070

http://www.w3.org/2001/XMLSchema#string

P698

19745746

http://www.w3.org/2001/XMLSchema#string

P921

life expectancy